When it comes to the clinical-stage immunotherapy company discussed in today’s article, the author notes that “Despite being years away from making the jump from clinical to a commercial stage company, there have been numerous instances in the past several years of the stock seeing 100% or greater returns over periods of three months or less.” Given this, and with shares looking undervalued, he believes the stock presents a compelling opportunity for significant gains in the near- to medium-term. For more, CLICK HERE.